Eikon Therapeutics filings document its transition to a Nasdaq-listed public company, its common stock registration, governance documents, financial results, and clinical and corporate updates. The company’s Form 8-K disclosures include results of operations and financial condition, exhibits containing press releases, and amendments to its certificate of incorporation and bylaws in connection with its initial public offering.
The filings also identify Eikon’s common stock, par value, trading symbol, Nasdaq listing, and public-company governance framework. For this clinical-stage biopharmaceutical issuer, regulatory disclosures center on capital structure, shareholder matters, clinical program updates, and corporate reporting obligations.
FRAZIER KENNETH C reported acquisition or exercise transactions in this Form 4 filing.
Eikon Therapeutics director Kenneth C. Frazier reported a new stock option grant covering 25,873 shares of Eikon Therapeutics common stock on March 2, 2026. The option vests in equal monthly installments over 48 months, conditioned on his continued service with the company.
PERLMUTTER ROGER M reported acquisition or exercise transactions in this Form 4 filing.
Eikon Therapeutics director and officer Roger M. Perlmutter received a grant of stock options covering 268,176 shares of the company’s stock. The options were awarded at no cash cost on the grant date. According to the vesting terms, 1/48 of the underlying shares vest monthly over 48 months, contingent on his continued service.
Eikon Therapeutics, Inc. reported that executive Benjamin Bruno Thorner received a grant of stock options covering 67,044 shares of the company’s stock. The options have an exercise price of $0.00 per share and represent a new award rather than an open-market purchase.
According to the vesting terms, one forty-eighth of the option shares will vest on each monthly anniversary of the vesting start date over 48 months, as long as Thorner continues to provide service to the company. This structure ties the award to multi-year retention and ongoing employment.
Eikon Therapeutics Chief Medical Officer Roy D. Baynes reported an option grant giving him rights to acquire 134,088 shares of company stock at an exercise price of $0.00 per share. The option vests in equal monthly installments over 48 months, conditioned on his continued service.
Eikon Therapeutics Chief Financial Officer receives new stock option grant. CFO Alfred Lloyd Bowie Jr. was granted stock options for 67,044 shares of Eikon Therapeutics, Inc. common stock on March 2, 2026, at an exercise price of $0.00 per share, recorded as a grant or award acquisition.
The option vests over four years: 1/48th of the underlying shares vest on each monthly anniversary of the vesting start date for 48 months, provided he continues in service through each vesting date. Following this grant, he directly holds options covering 67,044 shares.
Eikon Therapeutics ownership update: Abu Dhabi Investment Authority reports beneficial ownership of 2,816,714 shares of common stock, representing 5.2% of the class. The filing cites a shares outstanding base of 53,984,337 after giving effect to the offering described in the prospectus filed pursuant to Rule 424(b)(4) on February 5, 2026.
Platinum Falcon B 2018 RSC Limited is reported as the direct owner of 1,147,138 shares (shown as 2.1% of the class); Platinum Falcon is a wholly owned subsidiary of Abu Dhabi Investment Authority and certain voting/dispositive powers are shared between them.
The Column Group investment entities and principals have disclosed a large ownership position in Eikon Therapeutics, Inc. common stock. Together, they report beneficial ownership of 6,353,712 shares, representing 11.6% of Eikon’s outstanding common stock.
The stake is held through multiple venture funds and includes shares underlying warrants exercisable within 60 days. The position stems from preferred stock investments made between 2019 and 2025 that converted into common stock at Eikon’s initial public offering, plus additional common shares purchased in the IPO at $18 per share.
The investors describe their holdings as for general investment purposes and may increase or decrease their position over time. They also hold registration rights under an investors’ rights agreement and have agreed to 180-day lock-up restrictions following the IPO underwriting agreement.
Eikon Therapeutics, Inc. received a Schedule 13G filing from a group of Foresite Capital investment funds and their affiliated managers, disclosing a significant passive ownership stake in its common stock. The filing reports that various Foresite Capital funds and entities collectively attribute beneficial ownership to James B. Tananbaum of 4,148,519 shares, representing 7.7% of the common stock, based on 53,984,337 shares outstanding as of February 4, 2026.
Individual Foresite vehicles report smaller positions, including Foresite Capital Fund IV, L.P. with 1,960,774 shares (3.6%), Foresite Capital Fund V, L.P. with 1,353,168 shares (2.5%), Foresite Capital Opportunity Fund V, L.P. with 425,852 shares (0.8%), and Foresite Capital VI-A, LLC with 408,725 shares (0.8%). Each entity reports sole voting and dispositive power over its shares, with those powers ultimately attributable to Tananbaum through the general partner and managing member structures.
The Reporting Persons certify that the securities were not acquired and are not held for the purpose or effect of changing or influencing control of Eikon Therapeutics, indicating a passive investment posture consistent with a Schedule 13G filing.
Eikon Therapeutics, Inc. insider Roger M. Perlmutter, the company’s Chief Executive Officer and Director, indirectly acquired 284,857 shares of common stock on February 6, 2026 through derivative conversions tied to the company’s initial public offering.
Series A-1 Preferred Stock representing 1,268,891 shares and Series D Preferred Stock representing 855,512 shares each converted into common stock immediately prior to the IPO closing on a 1-for-7.4578 basis. The resulting common shares are held indirectly for Perlmutter’s benefit through Perlmutter Consulting, Inc., in which he had the sole pecuniary interest.
Entities affiliated with The Column Group reported sizable ownership changes in Eikon Therapeutics, Inc. (EIKN) tied to the company’s initial public offering. On February 6, 2026, multiple funds converted preferred stock into common and also bought additional shares.
The Column Group IV, LP, IV-A, LP and Opportunity III, LP converted Series A, A-1, C-1 and D preferred shares into common stock at an approximate 0.1340878-to-1 ratio and now hold indirect positions including 4,312,139, 148,840 and 1,319,164 common shares, respectively. On the same date, these entities also made open-market purchases of 1,437,323, 49,556 and 630,881 common shares at $18 per share. The filing states that the reporting persons disclaim beneficial ownership beyond their pecuniary interest.